Eli Lilly and Co. has reached an agreement with pharmaceutical Cipla to market tirzepatide, the active ingredient in Lilly’s weight loss and Type 2 diabetes treatments, under a separate brand name in Cipla’s home country of India.
Read MoreShares of Eli Lilly and Novo Nordisk fell Friday, Oct. 17 after Pres. Donald Trump said the price of the weight-loss drug Ozempic could soon drop to $150 a month.
Read MoreIndianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company’s second-quarter earnings report, alongside results from a closely watched trial of its experimental weight-loss pill.
Read MoreLawsuits from at least 26 patients have been filed in Marion County against Eli Lilly and Co. for its marketing of the drugs GLP-1 Trulicity and Mounjaro, claiming the treatments for diabetes and obesity had adverse side effects that the company downplayed or did not mention in advertising.
Read MoreAccording to a new BioCrossroads report, in 2024, Indiana was the largest national exporter of life science products and the industry generated $99 billion in economic activity.
Read MoreShares of Eli Lilly and Co. took a two-day slide after competitor Roche announced positive results in an early-stage study on its obesity drug.
Read More
